Klotho Plasmid Gene Therapy for Prevention in Humans
This clinical trial aims to evaluate the safety and impact of Klotho plasmid gene therapy in humans for prevention purposes. We will measure changes in various biomarkers such as serum alpha-Klotho, FGF23, parathyroid hormone, vitamin D, phosphorus, and cystatin C levels, as well as monitor any adverse events.
Injectable Plasmid Klotho Gene Therapy
Prevention Study
Summary
Study start date: October 6, 2025
Actual date on which the first participant was enrolled.This study aims to explore the safety and effects of a new gene therapy involving the Klotho gene. The Klotho gene is thought to be beneficial for improving memory, kidney function, and overall health and longevity. This investigation is especially relevant for healthy individuals, as the therapy's potential to enhance general health and cognitive abilities could lead to better quality of life and longer lifespan. Understanding these effects may also help in developing treatments for age-related health issues. Participants in this study will undergo various health and cognitive assessments both before and after receiving the gene therapy. The therapy is administered through a small injection into the fat of the abdomen. To measure the results, researchers will conduct blood tests, health screenings, and cognitive evaluations at multiple points during the study. Although the study takes place outside of the U.S. for the treatment portion, the evaluations before and after the treatment will occur in the U.S. The assessments aim to determine any improvements in health and cognitive functions after receiving the therapy.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.24 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Prevention Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 23 to 90 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
GARM Clinic
Roatán, Honduras